Two injections, two entirely different jobs

Both injections go into the hip joint — and that is roughly where the similarity ends.

ChondroFiller injection places a Type I collagen scaffold directly inside a focal cartilage defect, providing a physical matrix that the joint's own progenitor cells can migrate into and remodel. Hyaluronic acid (HA) adds a lubricating fluid to the whole joint space, reducing friction where natural synovial fluid has thinned with age or wear. One fills a discrete structural gap; the other oils the whole surface. A clinical shorthand that holds up: filling a pothole versus lubricating the road — neither job is wrong, but confusing them means the wrong treatment reaches the wrong hip.

The distinction matters because the hip joint can fail in two structurally different ways: a focal, contained cartilage defect on the femoral head or acetabulum, or diffuse osteoarthritic wear spread across the joint surface. These are opposite conditions, and they call for opposite approaches. Patient selection — not product preference — is the central clinical decision.

How ChondroFiller injection works inside the hip

The ChondroFiller injection is a CE-marked Class III medical device — acellular, supplied as two liquids that combine at body temperature (30–33°C) and gel within approximately three to five minutes. The collagen itself is Type I, extracted from rat-tail tendon using a weak-acid process that preserves the telopeptide regions at the ends of each collagen molecule; this matters because those regions allow the fibres to cross-link in a way that more closely resembles native cartilage matrix than enzyme-processed alternatives.

Once guided into a focal defect on the femoral head or acetabulum under real-time ultrasound, the gel sets inside the defect boundary, forming a dimensionally stable three-dimensional scaffold. It does not simply fill the space — it gives the body's own progenitor cells a framework to migrate into and begin remodelling. This process, matrix-induced chondrogenesis, has been confirmed biologically: a 2025 ex vivo osteochondral study measured a 2.4-fold increase in DNA content within the scaffold by day 14, demonstrating active cell recruitment rather than passive occupancy.

Ultrasound guidance is not optional for hip injections. Landmark-guided technique misses the intra-articular space in 28–30% of cases; for ChondroFiller, precise placement is structurally critical — the gel must set within the defect, not disperse into the joint cavity. The procedure is performed as an outpatient under local anaesthesia.

One practical aftercare point follows from the scaffold's early biology: a 2024 biomechanical study found the gel is initially unstable under full cyclic loading, so protected weight-bearing is needed for a period after injection while the scaffold stabilises and cell integration begins.

How hyaluronic acid injection works in the hip

Healthy synovial fluid contains hyaluronic acid at concentrations that give it a thick, gel-like consistency — a property that both lubricates articulating surfaces and absorbs compressive load. In hip osteoarthritis, natural HA concentration falls and chain length shortens, leaving joint fluid thinner and less protective.

An intra-articular HA injection replenishes this by raising synovial fluid viscosity across the entire hip joint space. The effect is distributed rather than localised: HA does not form a physical structure, occupy a defect, or provide a matrix for cell migration. Its action is primarily symptomatic — reducing friction and, through short-term anti-inflammatory effects, easing pain and stiffness. Because the joint clears injected HA within weeks, any sustained benefit reflects improved lubrication rather than structural change to cartilage architecture.

This makes HA most appropriate for diffuse, generalised hip osteoarthritis, where wear is spread across the joint surface rather than contained in a discrete defect — an indication profile directly opposite to ChondroFiller injection.

Molecular weight has practical prescribing relevance. A 2025 Level I systematic review of 9 RCTs (982 hip OA patients) found that high molecular weight (HMW) HA produced significantly lower VAS pain scores than medium molecular weight (MMW) HA at four to six months (MD −1.4, 95% CI −2.1 to −0.7, P<0.0001). However, a contemporaneous 2025 meta-analysis of four RCTs (n=823) found no statistically significant advantage of HMW HA over corticosteroids, PRP, or saline for hip OA outcomes, so the comparative benefit remains genuinely uncertain.

Which patients are suited to which treatment

The determining question is not which injection a patient prefers, but what the hip's imaging actually shows. Diagnosis drives the pathway — a focal cartilage defect and diffuse osteoarthritis are structurally different conditions that do not respond to the same treatment.

ChondroFiller injection is suited to patients with a discrete, contained lesion on the femoral head or acetabulum — typically Grade III or IV cartilage loss confined to a specific zone, in a hip with limited background osteoarthritis (Tönnis grade 0 or 1). Tönnis grading is a radiographic measure of how widespread joint-surface wear has become: grade 0–1 indicates minimal or mild generalised change; grade 2–3 reflects moderate to severe established arthritis across the joint. The hip-specific cohort study by Knapik et al. (Journal of Hip Preservation Surgery, 2021; n=26; 12–60 months) shows this distinction clearly: 17 of 21 evaluable patients with focal acetabular lesions achieved good or excellent MRI outcomes, whereas those with pre-existing Tönnis grade 2–3 osteoarthritis had poor results regardless of lesion treatment. Applying ChondroFiller injection in advanced background OA is a patient-selection error — the scaffold addresses a focal site of loss, not joint-wide surface degeneration.

Defect size is assessed on imaging before any decision is made. ChondroFiller scaffold typically covers lesions up to approximately 3 cm², extendable to 6 cm² in suitable anatomy, with containment and surrounding cartilage health both evaluated before proceeding.

Hyaluronic acid injection is appropriate where the opposite picture is present — diffuse, generalised wear spread across the joint surface without a discrete focal defect to scaffold. In that setting, lubricating the whole joint environment is the clinically correct aim.

Where both treatments are under consideration, the clinical assessment and imaging findings determine which, if either, is appropriate — not patient preference between two otherwise comparable options.

What the clinical evidence currently shows

Published data on ChondroFiller injection for the hip rests on a dedicated cohort study: Knapik et al. (Journal of Hip Preservation Surgery, 2021; n=26; follow-up 12–60 months), in which 17 of 21 evaluable patients with acetabular cartilage lesions greater than 2 cm² achieved good or excellent MRI outcomes. A separate hip-focused study by Perez-Carro et al. (PMC8322278, 2021) confirmed that injectable delivery into full-thickness acetabular defects is technically feasible, describing promising clinical results. Biological rationale is further supported by a multicenter RCT showing MRI-confirmed scaffold integration and significant IKDC score improvement with no adverse events — though this trial was conducted at the knee rather than the hip, so it contributes mechanistic confidence rather than hip-specific outcome data. A hip-specific randomised controlled trial for ChondroFiller injection does not yet exist.

For hyaluronic acid in hip osteoarthritis, two 2025 studies arrive at different conclusions. A Level I systematic review of 9 RCTs (982 patients) found statistically significant improvements in WOMAC and VAS pain scores, with high molecular weight HA outperforming medium molecular weight at four to six months. A separate meta-analysis of 4 RCTs (823 patients) found no statistically significant advantage of high molecular weight HA over corticosteroids, PRP, or saline. Neither study is wrong; they reflect the genuine limits of the current hip OA evidence base.

No head-to-head trial comparing ChondroFiller injection directly with HA in the hip joint exists. In practice, this means neither treatment can be claimed superior to the other in a controlled sense — the choice is made on the basis of what the hip's imaging actually shows, which is why accurate diagnosis precedes any injection discussion at Lincolnshire Hip.

Practical questions about the procedure and next steps

Both procedures take place in an outpatient setting under local anaesthesia — no hospital admission or general anaesthetic is required for either.

Delivery accuracy in the hip matters greatly, and image-guided technique is standard practice for both ChondroFiller and HA injections. Patients should confirm that ultrasound guidance will be used rather than landmark-based placement; the reasons for this are covered in the earlier mechanism section.

After a ChondroFiller injection, a period of protected weight-bearing is advised while the collagen scaffold stabilises within the defect. This is a routine part of aftercare rather than a complication signal, and the clinician will specify the duration at the time of the procedure.

HA injections involve one to three sessions depending on the product formulation — longer-acting cross-linked preparations such as Durolane are typically given as a single dose. No loading restriction applies after HA injection.

Lincolnshire Hip, part of the MSK Doctors group, accepts patients without a GP referral, with clinics in Sleaford and Grantham. Assessment begins with imaging to confirm whether a focal defect or diffuse osteoarthritis is the primary finding, because that distinction — not patient preference — determines which injection pathway, if any, is appropriate. The most useful question to bring to a consultation is not which injection to choose, but what the hip's imaging actually shows.

1. [1] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Intra-articular hyaluronic acid injections for hip osteoarthritis: a level I systematic review. (2025). https://doi.org/10.1007/s00590-025-04292-7 https://doi.org/10.1007/s00590-025-04292-7
5. [5] Viscosupplementation with High Molecular Weight Hyaluronic Acid for Hip Osteoarthritis: An Updated Systematic Review and Meta-Analysis of RCTs. (2025). https://doi.org/10.1055/s-0046-1819579 https://doi.org/10.1055/s-0046-1819579
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z